Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark X Sliwkowski

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Cancer Cell|May 18, 2013
Oncogenic ERBB3 mutations in human cancersBijay S Jaiswal, Noelyn M Kljavin, Eric W Stawiski, et al.
Nature Biotechnology|July 22, 2008
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R Junutula, Helga Raab, Suzanna Clark, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Cancer Cell|May 18, 2013
Oncogenic ERBB3 mutations in human cancersBijay S Jaiswal, Noelyn M Kljavin, Eric W Stawiski, et al.
Nature Biotechnology|July 22, 2008
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R Junutula, Helga Raab, Suzanna Clark, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Pageof 5